Replimune Group

REPL Lead: Approved ★ Read the deep dive → 12 Biotech Distilled articles ↓

Most recent annual filing: 2026-06-29

Catalyst timeline

RP2 readoutend of 2026RP2 readout, end of 2026, notable
Shareholder vote on authorized sharesSep 15, 2026Shareholder vote on authorized shares, Sep 15, 2026, routine
RP2 readout4Q 2026RP2 readout, 4Q 2026, notable
RP2 corporate update1Q 2027RP2 corporate update, 1Q 2027, routine
RP1 interim2H 2027RP1 interim, 2H 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

TUDRIQEV

vusolimogene oderparepvec · vusolimogene oderparepvec-wtpg · RP1

Gene Therapy

Melanoma Approved intratumoral BMS NCT03767348

vusolimogene oderparepvec

RP1

Gene Therapy

Cutaneous Squamous Cell Carcinoma Phase 2 intratumoral Bristol Myers Squibb NCT04050436

sturlimgene erparepvec

RP2

Gene Therapy Target: CTLA-4

Uveal Melanoma Phase 2 phase 2/3 trial intratumoral Bristol Myers Squibb NCT06581406
Hepatocellular Carcinoma Phase 2 intratumoral Roche NCT05733598
Biliary Tract Cancer Phase 2 intratumoral NCT04336241

Technology platforms

RPx

Proprietary oncolytic immunotherapy platform based on an engineered HSV-1 backbone with multiple immune-activating payloads (GALV-GP R(-), GM-CSF, anti-CTLA-4, CD40L, 4-1BBL); designed for intratumoral administration to induce local and systemic anti-tumor immunity; focus areas: skin cancers, liver cancers, uveal melanoma, and other solid tumors

Discontinued (1)

RP3 — undisclosed · program deprioritized; not pursuing further development at this time

Biotech Distilled coverage (12)

2026-08-15 UPDATE: Replimune (REPL) - The Confirmatory Clock Just Moved to 2030 🔒 Paid
2026-08-11 UPDATE: Replimune (REPL) - The Raise Lands, and the Stock Goes Up 🔒 Paid
2026-08-08 UPDATE: Replimune (REPL) - The Launch Deck Answers the Question I Ended On 🔒 Paid
2026-08-07 UPDATE: Replimune (REPL) - Approved, With an Asterisk in the Denominator 🔒 Paid
2026-07-31 UPDATE: Replimune (REPL) - 10 to 3 🔒 Paid
2026-07-30 UPDATE: Replimune (REPL) - The Panel Says Yes 🔒 Paid
2026-07-24 UPDATE: Replimune (REPL) - Baker Bros Gets Its Exit Ramp Six Days Before the AdCom 🔒 Paid
2026-06-26 UPDATE: Replimune (REPL) - The Clock Is Set
2026-06-02 UPDATE: Replimune (REPL) - ASCO Delivers the Backstop 🔒 Paid
2026-05-29 UPDATE: Replimune (REPL) - The FDA Blinks
2026-04-10 UPDATE: Replimune (REPL) - The Hammer Drops 🔒 Paid
2026-02-17 Replimune (REPL): Scientific Deep Dive for RP1, RP2, and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.